Fawad Butt, Author at MedCity News medcitynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medcitynews.com Daily Mail and Mail on Sunday newspapers.
MedCity News
Truepill becomes a ‘triple threat’ with diagnostics
Truepill, the company operating behind-the-scenes to help digital health companies with pharmacy fulfillment and telehealth visits, has added a third feature: at home testing. CEO Umar Afridi hopes the trio of services will create a seamless experience for most people’s basic health needs.
Shares0
Truepill, a company operating behind-the-scenes of several well-known digital health brands and health plans, added another tool to its repertoire: diagnostics. The San Francisco-based company is now ‘triple threat’ of sorts, offering white-labeled pharmacy fulfillment, telehealth and lab testing all in one place.
“There’s no other company that offers all three under one roof where it’s a seamless experience,” CEO Umar Afridi said in a phone interview.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
5 Minute Public Outdoor Masturbation Not Safe For Nature Watch me masturbate with a dildo in a nature reserve public footpath! At least 8 people walked past and saw me fuck myself. but that didn t stop me HD 1080P
Other download now products by LunaVesperasee more
Public Health England
Vaccines highly effective against B.1.617.2 variant after 2 doses
New study by PHE shows for the first time that 2 doses of the COVID-19 vaccines are highly effective against the B.1.617.2 variant first identified in India.
Vaccine effectiveness against symptomatic disease from the B.1.617.2 variant is similar after 2 doses compared to the B.1.1.7 (Kent) variant dominant in the UK, and we expect to see even higher levels of effectiveness against hospitalisation and death.
The study found that, for the period from 5 April to 16 May:
the Pfizer-BioNTech vaccine was 88% effective against symptomatic disease from the B.1.617.2 variant 2 weeks after the second dose, compared to 93% effectiveness against the B.1.1.7 variant